Print this page
-
A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma.
Protocol: 142301Applicable Disease Sites: Brain and Nervous System
-
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients with Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma.
Protocol: 142502Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)
Protocol: 142504Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma.
Protocol: 142301Applicable Disease Sites: Brain and Nervous System
-
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter and EGFRvIII.
Protocol: 142602Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients with Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma.
Protocol: 142502Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)
Protocol: 142504Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter and EGFRvIII.
Protocol: 142602Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System
- 1
- 2